To investiagte the therapeutic effect, a pivotal phase III, multicenter, randomized study of APR-246 in combination with azacitidine versus azacitidine alone in patients with TP53-mutant MDS is ongoing (NCT03745716). This evidence concerns the gene TP53 and myelodysplastic syndrome.